Terms: = Prostate cancer AND BTK, AGMX1, 695, ENSG00000010671, XLA, IMD1, RP1-164F3_2, MGC126262, BPK, ATK, MGC126261, Q06187, AT, PSCTK1 AND Staging
1865 results:
1. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
[TBL] [Abstract] [Full Text] [Related]
2. Low-Density Lipoprotein Cholesterol and prostate cancer: A Retrospective Study.
Hu P; Cheng R; Chen G; Hu X; Shen Y
Arch Esp Urol; 2024 Apr; 77(3):229-234. PubMed ID: 38715162
[TBL] [Abstract] [Full Text] [Related]
3. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
4. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
5. A pictorial view on false positive findings of
Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D
Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
[TBL] [Abstract] [Full Text] [Related]
6. Tripedal DNA Walker as a Signal Amplifier Combined with a Potential-Resolved Multicolor Electrochemiluminescence Strategy for Ultrasensitive Detection of prostate cancer staging Indicators.
Wang YZ; Zhang YQ; Liu Y; Li YR; Li ML; Meng GR; Mi L; Hu YH; Xu JJ
Anal Chem; 2024 Apr; 96(15):5852-5859. PubMed ID: 38556977
[TBL] [Abstract] [Full Text] [Related]
7. Extended pelvic lymph node dissection in robot-assisted radical prostatectomy is an independent risk factor for major complications.
Baas DJH; de Baaij JMS; Sedelaar JPM; Hoekstra RJ; Vrijhof HJEJ; Somford DM; van Basten JA
J Robot Surg; 2024 Mar; 18(1):140. PubMed ID: 38554195
[TBL] [Abstract] [Full Text] [Related]
8. Extra-prostatic extension grading system: correlation with MRI features and integration of capsular enhancement sign for "enhanced" detection of T3a lesions.
Martini F; Pigati M; Mattiauda M; Ponzano M; Piol N; Pigozzi S; Spina B; Cittadini G; Giasotto V; Zawaideh JP
Br J Radiol; 2024 May; 97(1157):971-979. PubMed ID: 38544291
[TBL] [Abstract] [Full Text] [Related]
9. Comparison of Ga-PSMA PET MRI with mpMRI in localization and regional staging of prostate cancer.
Deka H; Pooleri GK; Suguna B; Rajeshkannan R; Sekhar R; Bindhu MR; Prasad V
World J Urol; 2024 Mar; 42(1):153. PubMed ID: 38483621
[TBL] [Abstract] [Full Text] [Related]
10. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
11. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract] [Full Text] [Related]
12. Macroscopy of specimens from the genitourinary system.
Varma M; Dormer J
J Clin Pathol; 2024 Feb; 77(3):177-183. PubMed ID: 38373783
[TBL] [Abstract] [Full Text] [Related]
13. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
14. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
Singhal T; Singh P; Parida GK; Agrawal K
Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
[TBL] [Abstract] [Full Text] [Related]
15. Intraductal prostate cancer Affinity for Lymphatic-Predominant Metastases Through
Bernardino R; Sayyid RK; Lajkosz K; Al-Daqqaq Z; Tiwari R; Cockburn J; Leão R; Metser U; Berlin A; van der Kwast T; Fleshner NE
J Urol; 2024 Apr; 211(4):586-593. PubMed ID: 38299501
[TBL] [Abstract] [Full Text] [Related]
16. The Ability of the STAR-CAP staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
17. Combined whole-body dynamic and static PET/CT with low-dose [
Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
[TBL] [Abstract] [Full Text] [Related]
18. prostate cancer Risk Stratification by Simple Scoring of the Current pT3 Lesions: A Proposal for a New Pathologic T-staging System.
Miyamoto H; Teramoto Y; Numbere N; Wang Y; Joseph JV
Mod Pathol; 2024 Mar; 37(3):100429. PubMed ID: 38266919
[TBL] [Abstract] [Full Text] [Related]
19. Role of non-contrast CT component of prostate-specific membrane antigen PET/CT scan in the detection of peripheral zone prostate cancer.
Aggarwal P; Krishna Kumar RG; Das CJ; Kubihal V; Subudhi TK; Khan MA; Kumar R
Br J Radiol; 2024 Jan; 97(1153):195-200. PubMed ID: 38263835
[TBL] [Abstract] [Full Text] [Related]
20. Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients.
Falkenbach F; Kachanov M; Leyh-Bannurah SR; Maurer T; Knipper S; Köhler D; Graefen M; Sauter G; Budäus L
World J Urol; 2024 Jan; 42(1):38. PubMed ID: 38244095
[TBL] [Abstract] [Full Text] [Related]
[Next]